Latest news
Alterity CEO Set to Present at Canaccord Growth Conference - Stock TitanStock Titan · Thu, 06 Aug 2026 11:25:00 GMTAlterity Therapeutics (NASDAQ: ATHE) plans Canaccord Growth Conference talk - Stock TitanStock Titan · Thu, 06 Aug 2026 10:06:42 GMTAlterity Therapeutics clears FDA Phase 2 hurdle, plans Phase 3 trial for MSA drug ATH434 by end of 2026 - PluangPluang · Thu, 30 Jul 2026 12:02:41 GMTDasher Neuroscience Completes Patient Enrollment in Phase 2 Global Clinical Trial of Lead AI Drug Candidate YA-101 for Multiple System Atrophy (MSA) - Yahoo FinanceYahoo Finance · Tue, 28 Jul 2026 07:00:00 GMT